Pay in 4 interest-free payments of $5.19 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The Phase 3 ABTECT program comprised two double-blind, placebo-controlled induction RCTs (NCT05507203 and NCT05507216) testing 25mg and 50mg once-daily doses versus placebo in 1,275 patients across 600+ sites in 36 countries, with the primary endpoint of clinical remission at week 8, enrolling patients with inadequate response to conventional or advanced therapies including the largest JAK inhibitor-experienced population in UC trials (79)
Specifically, we measured oxygen consumption rate (OCR) to assess mitochondrial respiration, including basal respiration, ATP production, and maximal respiratory capacity
Researchers are encouraged to consult any product labeling to maintain integrity and reliability in experimental results
Updated Phase 3 Data from 2025: The Numbers Got Even Better In December 2025, Eli Lilly released topline results from the TRIUMPH-4 Phase 3 trial, and the numbers exceeded even the most optimistic projections from Wall Street analysts
They also act on the Central Nervous System (Brain) to suppress appetite, and guess what else they CAN do
As of January 2026, 13 states (Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia, and Wisconsin) cover GLP-1 receptor agonists (such as Wegovy) for weight loss
